The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy
Open accessAbstract
Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the orchestration of metabolic pathways in regulating ferroptosis will provide new insights into TNBC therapeutic strategies. Here, we integrated the multiomics data of our large TNBC cohort (n = 465) to develop the ferroptosis atlas. We discovered that TNBCs had heterogeneous phenotypes in ferroptosis-related metabolites and metabolic pathways. The luminal androgen receptor (LAR) subtype of TNBC was characterized by the upregulation of oxidized phosphatidylethanolamines and glutathione metabolism (especially GPX4), which allowed the utilization of GPX4 inhibitors to induce ferroptosis. Furthermore, we verified that GPX4 inhibition not only induced tumor ferroptosis but also enhanced antitumor immunity. The combination of GPX4 inhibitors and anti-PD1 possessed greater therapeutic efficacy than monotherapy. Clinically, higher GPX4 expression correlated with lower cytolytic scores and worse prognosis in immunotherapy cohorts. Collectively, this study demonstrated the ferroptosis landscape of TNBC and revealed an innovative immunotherapy combination strategy for refractory LAR tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2239 · Cited by 4,293
Ferroptosis: molecular mechanisms and health implications
Tang, D., Chen, X., Kang, R., & Kroemer, G. (2021) · Cell Research · doi:10.1038/s41422-020-00441-1 · Cited by 4,256
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
Bersuker, K., Hendricks, J. M., Li, Z., Magtanong, L., Ford, B., Tang, P. H., Roberts, M. A., Tong, B., Maimone, T. J., Zoncu, R., et al. (2019) · Nature · doi:10.1038/s41586-019-1705-2 · Cited by 3,703
Broadening horizons: the role of ferroptosis in cancer
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00462-0 · Cited by 2,897
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Wang, W., Green, M., Choi, J. E., Gijón, M., Kennedy, P. D., Johnson, J. K., Liao, P., Lang, X., Kryczek, I., Sell, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1170-y · Cited by 2,880
Lipid peroxidation and ferroptosis: The role of GSH and GPx4
Ursini, F., & Maiorino, M. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.02.027 · Cited by 1,954
A single-cell and spatially resolved atlas of human breast cancers
Wu, S. Z., Al-Eryani, G., Roden, D. L., Junankar, S., Harvey, K., Andersson, A., Thennavan, A., Wang, C., Torpy, J. R., Bartonicek, N., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00911-1 · Cited by 1,775
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
The Metabolic Underpinnings of Ferroptosis
Zheng, J., & Conrad, M. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.011 · Cited by 1,329
Intercellular interaction dictates cancer cell ferroptosis via NF2–YAP signalling
Wu, J., Minikes, A. M., Gao, M., Bian, H., Li, Y., Stockwell, B. R., Chen, Z.-N., & Jiang, X. (2019) · Nature · doi:10.1038/s41586-019-1426-6 · Cited by 1,110
Jiang, Y.-Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., Xiao, Y., Yu, K.-D., Liu, Y.-R., Yu, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.001 · Cited by 1,062
Self-citationLang, X., Green, M. D., Wang, W., Yu, J., Choi, J. E., Jiang, L., Liao, P., Zhou, J., Zhang, Q., Dow, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0338 · Cited by 1,047
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4
Liao, P., Wang, W., Wang, W., Kryczek, I., Li, X., Bian, Y., Sell, A., Wei, S., Grove, S., Johnson, J. K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.02.003 · Cited by 912
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
Denkert, C., Liedtke, C., Tutt, A., & von Minckwitz, G. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32454-0 · Cited by 872
Gene expression markers of Tumor Infiltrating Leukocytes
Danaher, P., Warren, S., Dennis, L., D’Amico, L., White, A., Disis, M. L., Geller, M. A., Odunsi, K., Beechem, J., & Fling, S. P. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0215-8 · Cited by 806
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
Hakimi, A. A., Reznik, E., Lee, C.-H., Creighton, C. J., Brannon, A. R., Luna, A., Aksoy, B. A., Liu, E. M., Shen, R., Lee, W., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.004 · Cited by 798
Unsolved mysteries: How does lipid peroxidation cause ferroptosis?
Feng, H., & Stockwell, B. R. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2006203 · Cited by 759
Kim, S. E., Zhang, L., Ma, K., Riegman, M., Chen, F., Ingold, I., Conrad, M., Turker, M. Z., Gao, M., Jiang, X., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.164 · Cited by 622
Salinomycin kills cancer stem cells by sequestering iron in lysosomes
Mai, T. T., Hamaï, A., Hienzsch, A., Cañeque, T., Müller, S., Wicinski, J., Cabaud, O., Leroy, C., David, A., Acevedo, V., et al. (2017) · Nature Chemistry · doi:10.1038/nchem.2778 · Cited by 612
Prominin2 Drives Ferroptosis Resistance by Stimulating Iron Export
Brown, C. W., Amante, J. J., Chhoy, P., Elaimy, A. L., Liu, H., Zhu, L. J., Baer, C. E., Dixon, S. J., & Mercurio, A. M. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.10.007 · Cited by 575
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Characteristics and Biomarkers of Ferroptosis
Chen, X., Comish, P. B., Tang, D., & Kang, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.637162 · Cited by 504
Redox regulation of immunometabolism
Muri, J., & Kopf, M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00478-8 · Cited by 491
Hollern, D. P., Xu, N., Thennavan, A., Glodowski, C., Garcia-Recio, S., Mott, K. R., He, X., Garay, J. P., Carey-Ewend, K., Marron, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.028 · Cited by 478
Gong, Y., Ji, P., Yang, Y.-S., Xie, S., Yu, T.-J., Xiao, Y., Jin, M.-L., Ma, D., Guo, L.-W., Pei, Y.-C., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.012 · Cited by 467
Self-citationRody, A., Holtrich, U., Pusztai, L., Liedtke, C., Gaetje, R., Ruckhaeberle, E., Solbach, C., Hanker, L., Ahr, A., Metzler, D., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2234 · Cited by 460
Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy
Jiang, Q., Wang, K., Zhang, X., Ouyang, B., Liu, H., Pang, Z., & Yang, W. (2020) · Small · doi:10.1002/smll.202001704 · Cited by 426
Ding, Y., Chen, X., Liu, C., Ge, W., Wang, Q., Hao, X., Wang, M., Chen, Y., & Zhang, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01016-8 · Cited by 415
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., Gibbs, D. L., Weerasinghe, A., Huang, K.-L., Tokheim, C., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.033 · Cited by 399
Self-citationGaude, E., & Frezza, C. (2016) · Nature Communications · doi:10.1038/ncomms13041 · Cited by 375
Xiao, Y., Ma, D., Zhao, S., Suo, C., Shi, J., Xue, M.-Z., Ruan, M., Wang, H., Zhao, J., Li, Q., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3524 · Cited by 352
Self-citationEmerging role of 12/15-Lipoxygenase (ALOX15) in human pathologies
Singh, N. K., & Rao, G. N. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.11.001 · Cited by 345
Pusztai, L., Yau, C., Wolf, D. M., Han, H. S., Du, L., Wallace, A. M., String-Reasor, E., Boughey, J. C., Chien, A. J., Elias, A. D., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.009 · Cited by 337
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
Xiao, Y., Ma, D., Yang, Y.-S., Yang, F., Ding, J.-H., Gong, Y., Jiang, L., Ge, L.-P., Wu, S.-Y., Yu, Q., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00614-0 · Cited by 326
Self-citationTYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Jiang, Z., Lim, S.-O., Yan, M., Hsu, J. L., Yao, J., Wei, Y., Chang, S.-S., Yamaguchi, H., Lee, H.-H., Ke, B., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139434 · Cited by 325
Song, R., Li, T., Ye, J., Sun, F., Hou, B., Saeed, M., Gao, J., Wang, Y., Zhu, Q., Xu, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202101155 · Cited by 308
Self-citationJiang, Y.-Z., Liu, Y., Xiao, Y., Hu, X., Jiang, L., Zuo, W.-J., Ma, D., Ding, J., Zhu, X., Zou, J., et al. (2021) · Cell Research · doi:10.1038/s41422-020-0375-9 · Cited by 298
Self-citationSterol regulatory element binding protein 1 couples mechanical cues and lipid metabolism
Bertolio, R., Napoletano, F., Mano, M., Maurer-Stroh, S., Fantuz, M., Zannini, A., Bicciato, S., Sorrentino, G., & Del Sal, G. (2019) · Nature Communications · doi:10.1038/s41467-019-09152-7 · Cited by 297
CD44 regulates epigenetic plasticity by mediating iron endocytosis
Müller, S., Sindikubwabo, F., Cañeque, T., Lafon, A., Versini, A., Lombard, B., Loew, D., Wu, T.-D., Ginestier, C., Charafe-Jauffret, E., et al. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0513-5 · Cited by 288
Li, H., Yang, P., Wang, J., Zhang, J., Ma, Q., Jiang, Y., Wu, Y., Han, T., & Xiang, D. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01223-x · Cited by 273
Self-citationFu, J., Li, T., Yang, Y., Jiang, L., Wang, W., Fu, L., Zhu, Y., & Hao, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120537 · Cited by 231
Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis
Llabani, E., Hicklin, R. W., Lee, H. Y., Motika, S. E., Crawford, L. A., Weerapana, E., & Hergenrother, P. J. (2019) · Nature Chemistry · doi:10.1038/s41557-019-0261-6 · Cited by 230
Chen, T.-C., Chuang, J.-Y., Ko, C.-Y., Kao, T.-J., Yang, P.-Y., Yu, C.-H., Liu, M.-S., Hu, S.-L., Tsai, Y.-T., Chan, H., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2019.101413 · Cited by 228
Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer: A Review
Kono, M., Fujii, T., Lim, B., Karuturi, M. S., Tripathy, D., & Ueno, N. T. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4975 · Cited by 215
Fan, F., Liu, P., Bao, R., Chen, J., Zhou, M., Mo, Z., Ma, Y., Liu, H., Zhou, Y., Cai, X., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1547 · Cited by 198
Zhao, S., Ma, D., Xiao, Y., Li, X.-M., Ma, J.-L., Zhang, H., Xu, X.-L., Lv, H., Jiang, W.-H., Yang, W.-T., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0982 · Cited by 197
Self-citationNassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J., Irani, S., Centenera, M. M., Helm, M., Shrestha, R. K., Moldovan, M., Don, A. S., et al. (2020) · eLife · doi:10.7554/elife.54166 · Cited by 197
Hu, S., Ma, J., Su, C., Chen, Y., Shu, Y., Qi, Z., Zhang, B., Shi, G., Zhang, Y., Zhang, Y., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.09.003 · Cited by 195
Emerging Regulatory Paradigms in Glutathione Metabolism
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-420117-0.00002-5 · Cited by 186
2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
Blomme, A., Ford, C. A., Mui, E., Patel, R., Ntala, C., Jamieson, L. E., Planque, M., McGregor, G. H., Peixoto, P., Hervouet, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16126-7 · Cited by 181
Maintaining and reprogramming genomic androgen receptor activity in prostate cancer
Mills, I. G. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3678 · Cited by 172
Lehmann, B. D., Abramson, V. G., Sanders, M. E., Mayer, E. L., Haddad, T. C., Nanda, R., Poznak, C. H. V., Storniolo, A. M., Nangia, J. R., Ericsson, P. I. G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2170 · Cited by 160
Zhang, J., Yang, J., Zuo, T., Ma, S., Xokrat, N., Hu, Z., Wang, Z., Xu, R., Wei, Y., & Shen, Q. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120429 · Cited by 144
Gu, Z., Liu, T., Liu, C., Yang, Y., Tang, J., Song, H., Wang, Y., Yang, Y., & Yu, C. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01401 · Cited by 133
Self-citationTherapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer
Tousignant, K. D., Rockstroh, A., Poad, B. L. J., Talebi, A., Young, R. S. E., Fard, A. T., Gupta, R., Zang, T., Wang, C., Lehman, M., et al. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-00217-6 · Cited by 123
Han, W., Duan, X., Ni, K., Li, Y., Chan, C., & Lin, W. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121315 · Cited by 103
Immunogenic and Non-immunogenic Cell Death in the Tumor Microenvironment
Pitt, J. M., Kroemer, G., & Zitvogel, L. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_5 · Cited by 102
Zhang, D., Cui, P., Dai, Z., Yang, B., Yao, X., Liu, Q., Hu, Z., & Zheng, X. (2019) · Nanoscale · doi:10.1039/c9nr05684j · Cited by 98
Han, W., Gao, S., Barrett, D., Ahmed, M., Han, D., Macoska, J., He, H., & Cai, C. (2017) · Oncogene · doi:10.1038/onc.2017.385 · Cited by 95
Tousignant, K. D., Rockstroh, A., Fard, A. T., Lehman, M., Wang, C., McPherson, S. J., Philp, L., Bartoniček, N., Dinger, M. E., Nelson, C. C., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1147 · Cited by 88
Yang, Y., Liu, T., Hu, C., Xia, H., Liu, W., Chen, J., Wu, S., Jiang, Y., Xu, Y., Liu, W., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.7976 · Cited by 54
Self-citationLiao, C., Glodowski, C. R., Fan, C., Liu, J., Mott, K. R., Kaushik, A., Vu, H., Locasale, J. W., McBrayer, S. K., DeBerardinis, R. J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2745 · Cited by 39
Petrov, P., Fernández-Murga, M. L., Conde, I., Martínez-Sena, T., Guzmán, C., Castell, J. V., & Jover, R. (2020) · Archives of Toxicology · doi:10.1007/s00204-019-02643-y · Cited by 22
Nantermet, P. V., Harada, S.-I., Liu, Y., Cheng, S., Johnson, C. A., Yu, Y., Kimme, D., Holder, D., Hodor, P. G., Phillips, R., et al. (2008) · Endocrinology · doi:10.1210/en.2007-1151 · Cited by 17
Androgen-Regulated microRNAs (AndroMiRs) as Novel Players in Adipogenesis
Jansen, J., Greither, T., & Behre, H. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225767 · Cited by 11
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Self-citationFerroptosis in cancer: from molecular mechanisms to therapeutic strategies
Zhou, Q., Meng, Y., Li, D., Yao, L., Le, J., Liu, Y., Sun, Y., Zeng, F., Chen, X., & Deng, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01769-5 · Cited by 890
Self-citationCold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Lei, G., Zhuang, L., & Gan, B. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.011 · Cited by 586
The diversified role of mitochondria in ferroptosis in cancer
Liu, Y., Lu, S., Wu, L.-L., Yang, L., Yang, L., & Wang, J. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06045-y · Cited by 440
Metadata
- Authors
- Yang, F., Xiao, Y., Ding, J.-H., Jin, X., Ma, D., Li, D.-Q., Shi, J.-X., Huang, W., Wang, Y.-P., Jiang, Y.-Z., & Shao, Z.-M.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 35
- Issue
- 1
- Pages
- 84-100.e8
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W4306410243
- Cited by
- 624
- References
- 71
- FWCI
- 67.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.